proteom
studi
reveal
import
inform
small
molecul
therapeut
case
studi
plasma
protein
lello
zolla
depart
environment
scienc
univers
tuscia
piazzal
viterbo
itali
abund
protein
serum
albumin
igg
act
molecular
spong
bind
transport
low
molecular
weight
proteinspeptid
drug
near
futur
pharmacoproteom
use
proteom
technolog
field
drug
discoveri
develop
interactom
branch
proteom
concern
identifi
interact
protein
allow
research
know
specif
protein
chang
occur
biolog
compart
respons
drug
administr
ii
design
small
novel
therapeut
molecul
extend
halfliv
carri
plasma
protein
blood
stream
advanc
field
open
new
avenu
tailormad
molecular
therapi
reduc
present
limit
treatment
aris
toxic
inefficiencyin
short
review
report
discuss
recent
develop
aris
use
proteom
tool
blood
plasma
protein
research
look
identif
protein
found
plasma
well
interact
small
molecul
drug
peptid
organ
chemic
metal
believ
research
demonstr
proteom
technolog
particular
pharmacoproteom
interactom
posttransl
modif
analysi
could
instrument
design
new
tailormad
drug
lead
substanti
improv
molecular
therapi
blood
plasma
complex
humanderiv
proteom
complex
enorm
rang
concentr
encount
across
popul
protein
compon
span
excess
ten
order
magnitud
whole
blood
plasma
difficult
specimen
analyz
creat
seriou
challeng
proteom
much
progress
alreadi
made
field
new
direct
put
forward
discuss
part
hupo
plasma
proteom
project
ppp
focu
effort
remain
challeng
ppp
initi
three
state
longterm
goal
make
comprehens
analysi
protein
constitu
plasma
ii
determin
extent
sourc
variat
individu
plasma
time
iii
determin
extent
variat
plasma
individu
within
across
popul
blood
plasma
known
contain
protein
deriv
blood
cell
bodi
tissu
may
end
cell
death
damag
caus
protein
releas
normal
cell
may
come
aberr
protein
secret
tumor
cell
recent
investig
examin
plasma
protein
compon
categori
reveal
mani
protein
detect
plasma
normal
associ
cell
ie
known
plasma
protein
cellular
leakag
protein
categor
accord
origin
locat
function
intracellular
protein
account
protein
identifi
membraneassoci
protein
includ
protein
membranebas
known
releas
plasma
ie
receptor
coreceptor
adhes
molecul
account
anoth
anoth
protein
found
cellular
origin
either
secret
occupi
extracellular
locat
identifi
specif
cytokin
cytokinerel
protein
protein
gener
consid
passeng
protein
transient
other
util
plasma
transport
local
mediat
cellular
respons
overal
group
least
character
possibl
interest
one
term
potenti
yield
biomark
protein
concentr
believ
rang
low
mgml
pgml
level
possibl
extend
level
detect
limit
tradit
elisa
assay
pg
ml
classic
plasma
protein
whose
activ
specif
local
plasma
human
serum
albumin
hsa
complement
compon
apolipoprotein
make
total
protein
found
plasma
approxim
protein
identifi
howev
known
function
henc
divers
popul
protein
deriv
rang
sourc
might
expect
analysi
extracellular
proteom
protein
circul
plasma
cellbas
proteom
necessari
complementari
exhaust
plasma
investig
one
strategi
appli
sever
recent
exampl
involv
use
secondari
tissu
fluid
interest
first
identifi
potenti
candid
biomark
screen
complementari
plasma
sampl
presenc
investig
highli
desir
diseas
marker
present
plasma
may
includ
protein
signific
potenti
earli
diseas
diagnosi
contain
inform
directli
reflect
pathophysiolog
state
repres
invalu
sourc
diagnost
inform
varieti
differ
diseas
thu
broad
inventori
plasma
protein
qualit
quantit
could
use
identif
put
protein
marker
diagnos
diseas
well
develop
new
therapeut
product
quantit
speak
core
plasma
protein
albumin
repres
total
plasma
protein
content
order
gl
immunoglobulin
ig
repres
total
protein
mass
lowabund
plasma
protein
tissu
leakag
cytokin
present
rang
picogram
nanogram
per
millilit
abund
protein
serum
albumin
igg
transferrin
known
act
carrier
hormon
lipoprotein
mani
protein
lipid
metal
may
fact
describ
molecular
spong
bind
transport
low
molecular
weight
lmw
proteinpeptid
speci
prevent
rapid
clearanc
renal
system
therebi
extend
halflif
blood
stream
although
estim
human
plasma
protein
display
associ
major
protein
found
associ
igg
protein
also
found
hsa
codeplet
group
suggest
possibl
weak
overlap
interact
protein
hsa
igg
see
fig
moreov
protein
circulatori
system
expos
varieti
proteas
chemic
oxid
plasma
rich
peptid
socal
peptidom
see
box
peptid
reveal
preval
associ
carrier
protein
ig
retain
sampl
peptidebas
proteom
studi
act
gener
sourc
random
peptid
sequenc
contribut
larg
librari
background
speci
abund
mgml
sampl
concentr
varieti
greatli
complic
process
peptid
detect
identif
plasma
protein
interact
appear
exhibit
littl
depend
protein
size
fact
small
plasma
protein
basic
prolinerich
peptid
pe
mw
da
igg
codeplet
protein
show
interact
specif
larg
protein
cardiac
titin
isoform
mw
da
typic
found
one
protein
interact
group
kind
inform
concern
interact
human
plasma
protein
use
studi
human
blood
systemsnetwork
biolog
evalu
possibl
protein
contamin
therapeut
protein
product
prepar
human
plasma
design
analyt
approach
deplet
high
abund
plasma
protein
effect
addit
could
use
help
design
protein
reduc
rate
clearanc
circulatori
system
particularli
import
small
protein
use
therapeut
agent
normal
small
uncomplex
protein
peptid
ie
less
kda
rapidli
clear
circul
enzymat
degrad
uptak
reticuloendotheli
system
glomerular
filtrat
discrimin
basi
molecular
size
charg
believ
circul
halflif
lmw
fraction
directli
relat
bind
affin
larg
high
abund
carrier
protein
drug
discoveri
today
volum
number
decemb
box
array
peptid
normal
present
within
circulatori
proteom
term
peptidom
could
rich
sourc
cancerspecif
diagnost
inform
provid
record
cellular
extracellular
enzymat
event
take
place
level
cancertissu
microenviron
new
inform
archiv
seem
show
peptid
vivo
bound
highabund
protein
albumin
measur
panel
peptidom
marker
might
sensit
specif
convent
biomark
approach
biomark
biolog
molecul
found
blood
bodi
fluid
tissu
sign
normal
abnorm
process
condit
diseas
biomark
may
also
use
see
well
bodi
respond
treatment
diseas
condit
measur
progress
diseas
effect
treatment
use
proteom
technolog
field
drug
discoveri
develop
toxicoproteom
use
global
protein
express
technolog
better
understand
environment
genet
factor
episod
acut
exposur
toxic
longterm
develop
diseas
primari
aim
toxicoproteom
discoveri
keymodifi
protein
determin
affect
pathway
develop
biomark
eventu
predict
toxic
use
proteom
technolog
tool
phosphorylationsitespecif
antibodi
assess
monitor
phosphoryl
state
variou
protein
involv
signal
pathway
cell
method
allow
quantit
measur
protein
two
separ
popul
mass
spectrometri
via
differenti
tag
protein
popul
cystein
residu
heavi
light
isotop
reagent
protein
microarray
compos
seri
immobil
spot
contain
homogen
heterogen
bait
molecul
spot
array
repres
antibodi
cell
phage
lysat
recombin
protein
peptid
nucleic
acid
array
queri
either
probe
label
antibodi
ligand
unknown
biolog
sampl
eg
cell
lysat
serum
sampl
contain
analyt
interest
directli
indirectli
tag
queri
molecul
signalgener
moieti
pattern
posit
neg
spot
gener
combinatori
ligand
librari
compos
million
divers
hexapeptid
bait
abl
captur
aspecif
peptid
protein
given
proteom
way
concentr
lowabund
proteom
drastic
cut
concentr
abund
compound
base
concept
onebead
onepeptid
approach
freeflow
electrophoresi
ffe
electrophoresi
carri
aqueou
medium
without
use
solid
matrix
acrylamid
use
separ
wide
varieti
charg
analyt
like
lowmolecular
weight
organ
compound
peptid
protein
protein
complex
membran
organel
whole
cell
aqueou
media
nativ
denatur
condit
analyt
inject
thin
laminar
separ
buffer
film
defin
electrophoret
mode
zone
electrophoresi
ief
isotachophoresi
deflect
electr
field
perpendicular
flow
direct
differenti
scan
calorimetri
differenti
scan
calorimetri
measur
differ
amount
heat
requir
increas
temperatur
chang
biolog
sampl
respect
unchang
one
refer
function
temperatur
differ
thermogram
blood
plasma
normal
diseas
individu
relat
concentr
abund
plasma
protein
rather
seem
aris
bind
interact
involv
yet
unknown
biomark
abund
plasma
protein
particularli
albumin
behavior
consist
interactom
hypothesi
interactom
fusion
scienc
biolog
informat
engin
provid
global
view
protein
famili
interact
network
involv
studi
interact
consequ
interact
among
protein
molecul
within
cell
use
compar
network
interact
within
speci
see
trait
network
vari
conserv
interactom
network
includ
certain
calcul
paramet
weigh
reliabl
given
interact
ie
edg
interactom
network
two
protein
also
qualifi
function
environ
around
given
protein
ie
node
interactom
network
strategi
devis
retard
clearanc
therapeut
protein
includ
coval
attach
polyethylen
glycol
dextran
chain
proteinprotein
crosslink
genet
modif
also
use
creat
chimera
therapeut
protein
interest
longliv
plasma
protein
like
albumin
igg
differ
protein
estim
commonli
present
plasma
low
rel
abund
dynam
rang
current
avail
proteom
techniqu
mass
spectrometri
ms
gel
electrophoresi
span
three
four
order
magnitud
approach
ten
order
magnitud
repres
plasma
protein
thu
signific
challeng
proteom
analysi
plasma
reveal
lowabund
protein
strategi
frequent
use
overcom
dynam
rang
problem
fraction
plasma
proteom
smaller
subset
andor
deplet
one
major
protein
immunoaffin
effici
way
deplet
protein
method
wide
use
immobil
antibodi
pack
column
cartridg
captur
sever
abund
protein
lower
protein
content
initi
amount
although
nontarget
protein
remov
process
shown
reproduc
multipl
orthogon
separ
step
also
use
strong
cation
exchang
chromatographi
follow
revers
phaseliquid
chromatographi
rplc
insolut
isoelectr
focus
ief
recent
novel
separ
approach
propos
use
freeflow
electrophoresi
ffe
separ
protein
peptid
solut
accord
pi
lcmsm
commerci
combinatori
ligand
librari
proteomin
avail
enabl
research
pick
lowabund
protein
anoth
innov
microflow
devic
prefraction
complex
low
volum
lowabund
sampl
also
enrich
specif
speci
protein
base
charg
andor
size
either
nativ
denatur
format
strategi
concomitantli
remov
proteinspeptid
associ
highli
abund
protein
target
deplet
recent
studi
focus
bind
properti
six
abund
serum
protein
investig
small
peptidesprotein
may
bound
protein
target
found
capabl
bind
sever
differ
peptideprotein
protein
total
uniqu
peptid
mani
clinic
use
biomark
result
suggest
one
hand
albumin
igg
deplet
protein
identif
may
actual
elimin
mani
valuabl
biomark
hand
identif
biomark
select
isol
protein
bound
abund
protein
serum
could
novel
proteom
strategi
gener
specif
sampl
loss
increas
separ
stage
best
solut
dilemma
maxim
effici
separ
stage
minim
sever
dimens
requir
character
complex
mixtur
state
proteom
approach
may
util
diseas
classif
well
develop
novel
biomark
relat
prognosi
diagnosi
choic
therapeut
regimen
gener
accept
biomark
origin
classic
plasma
secret
probabl
leakag
secret
shed
protein
specif
affect
tissu
cell
type
cellular
pathway
nevertheless
blood
still
logic
choic
biospecimen
becom
frequent
use
biomark
discoveri
matrix
date
drive
forc
biomark
discoveri
develop
bloodbas
assay
earli
detect
predict
therapeut
respons
follow
protein
biomark
identifi
biopsi
tissu
research
abl
examin
blood
determin
whether
biomark
circul
great
advantag
blood
test
much
less
invas
biopsi
downsid
protein
releas
around
liter
plasma
concentr
extrem
low
henc
need
extend
dynam
rang
protein
detect
proteom
come
although
blood
conveni
noninvas
fluid
monitor
biomark
pose
mani
challeng
perspect
protein
detect
probabl
greatest
potenti
applic
proteom
lie
investig
pathway
easili
target
small
molecul
therapeut
antibodi
among
challeng
face
clinic
proteom
abil
link
protein
express
profil
specif
diseas
phenotyp
identif
relev
biomark
develop
diagnost
tool
sens
proteom
expans
reductionist
biolog
singl
protein
analyz
high
throughput
fashion
arriv
understand
entir
system
intent
human
blood
proteom
fulli
describ
sever
biomark
emerg
particular
diseas
state
use
provid
fingerprint
diseas
obviou
implic
blood
donor
test
alreadi
systemat
search
underway
look
plasma
protein
biolog
indic
biomark
cancer
see
ref
suit
biomark
avail
earli
detect
stratif
distinct
subtyp
monitor
progress
respons
therapi
could
expect
signific
improv
clinic
outcom
cancer
patient
intent
develop
panel
biomark
allow
earli
detect
cancer
predict
probabl
respons
therapi
possibl
detect
singl
proteom
experi
despit
recent
progress
proteom
technolog
base
ms
howev
discoveri
novel
clinic
assess
tool
slow
partli
inher
difficulti
work
blood
hope
better
understand
limit
blood
compar
protein
profil
appreci
advantag
cancer
tissu
cancer
cell
secretom
greatli
enhanc
progress
compar
proteom
studi
bodi
fluid
schizophrenia
patient
carri
look
biomark
associ
protein
effort
understand
etiolog
schizophrenia
found
protein
express
ttr
tetram
apolipoprotein
e
apo
downregul
time
respect
schizophrenia
patient
compar
normal
control
studi
reveal
potenti
diagnost
cancer
biomark
use
blood
sjl
select
jame
lambert
mice
growth
rcsx
lymphoma
cell
induc
inflammatori
respons
stimul
v
b
cell
deplet
albumin
immunoglobulin
mous
nr
protein
identifi
sjl
mous
plasma
singl
experi
found
upregul
eg
acut
phase
reactant
protein
found
uniqu
tumorbear
mous
plasma
ie
haptoglobin
proteosom
subunit
fetuinb
zeta
antigen
remain
seen
whether
similar
uniqu
profil
occur
human
lymphoma
recent
studi
demonstr
sepsi
cancer
interalpha
inhibitor
protein
iaip
famili
structur
relat
serin
proteas
inhibitor
present
rel
high
concentr
human
plasma
suggest
suitabl
potenti
biomark
would
seem
logic
assum
better
understand
biolog
mechan
drug
toxic
develop
therapeut
resist
would
lead
develop
improv
therapeut
signific
util
clinic
research
context
pharmacoproteom
use
proteom
technolog
field
drug
discoveri
develop
see
fig
emerg
scienc
protein
drugact
biomark
defin
specif
protein
chang
total
protein
content
biolog
compart
occur
respons
drug
administr
contrast
genom
approach
applic
pharmacoproteom
virtu
stimulusinduc
may
amen
systemat
experiment
manipul
could
ultim
result
valid
biomark
also
character
behavior
specif
condit
associ
chemic
compound
librari
screen
strategi
pharmacoproteom
expect
acceler
discoveri
new
lead
compound
futur
drug
also
play
import
part
preclin
studi
provid
inform
mode
action
eventu
deleteri
side
effect
drug
hope
ongo
futur
proteom
studi
open
new
avenu
tailormad
molecular
therapi
reduc
present
limit
associ
treatment
toxic
effici
msbase
proteom
ideal
respect
offer
target
way
identifi
hundr
protein
peptid
biomark
simultan
obviou
potenti
discov
drugact
marker
often
priori
knowledg
particular
protein
like
chang
respons
drug
administr
sampl
enrich
narrow
dynam
rang
molecul
interest
must
detect
improv
separ
technolog
ms
extend
abil
find
identifi
protein
ever
wider
rang
rel
protein
concentr
ion
trap
instrument
supersed
greatli
improv
linear
ion
trap
mass
spectromet
time
steadi
decreas
diamet
lccapillari
column
result
increas
sensit
abil
quantifi
protein
improv
analysi
increas
order
magnitud
detect
dynam
rang
protein
would
pick
previous
sampl
similar
size
time
lcfticrm
fourier
transform
ion
cyclotron
drug
discoveri
today
volum
number
decemb
theoret
exampl
differenti
screen
plasma
protein
healthi
ill
treat
respond
resist
patient
gel
electrophoresi
appear
disappear
protein
spot
well
quantit
variat
protein
express
observ
reson
ms
technolog
provid
sensit
power
measur
platform
though
signific
potenti
exist
increas
dynam
rang
appli
case
limit
sampl
complex
rather
detect
limit
recent
howev
differenti
scan
calorimetri
provid
new
window
plasma
proteom
thermogram
plasma
diseas
individu
found
differ
dramat
normal
control
individu
also
differ
suffer
differ
ill
least
three
diseas
examin
arthriti
lyme
diseas
lupu
diseas
appear
distinct
characterist
thermogram
radic
differ
thermogram
seen
differ
diseas
state
seem
aris
bind
interact
involv
yet
unknown
biomark
abund
plasma
protein
particularli
albumin
behavior
consist
interactom
hypothesi
suggest
novel
use
calorimetri
diagnost
tool
care
approach
clinic
design
data
analysi
import
maxim
chanc
discov
meaning
drugact
marker
first
step
establish
link
drug
administr
result
biolog
quantifi
chang
strong
foundat
set
stage
datadriven
hypothesi
gener
test
establish
util
multidisciplinari
tool
expand
frontier
clinic
research
often
inform
avail
tissu
investig
circumst
proteinprofil
chang
respons
drug
treatment
serv
evid
cell
pharmacodynam
activ
data
use
establish
minimum
dose
earli
clinic
studi
broadli
target
proteom
also
hypothesi
gener
detect
druginduc
chang
also
lead
new
line
research
inquiri
field
drug
develop
pathophysiolog
clear
understand
proteom
variabl
control
condit
crucial
enabl
futur
clinic
studi
appropri
design
improv
contextu
interpret
data
obtain
pharmacoproteom
studi
also
import
establish
suitabl
time
period
drug
administr
analysi
primarili
allow
suffici
time
tissuetarget
drug
reach
pharmacokinet
steadi
state
explor
protein
profil
chang
ensur
minim
interfer
extran
factor
endogen
variabl
thu
maxim
probabl
identifi
even
subtl
druginduc
chang
variabl
individu
subject
could
potenti
affect
observ
unpair
comparison
studi
diseas
versu
healthi
volunt
taken
account
word
assum
pharmacodynam
respons
ident
chemic
biochem
stimuli
similar
among
healthi
individu
respons
differ
significantli
consist
patient
patholog
disord
varieti
factor
influenc
profil
individu
aspect
requir
investig
ascertain
use
biomark
ultim
prove
consequ
drug
develop
pharmacoproteom
limit
extracellular
proteom
analysi
blood
plasma
cellbas
proteom
analysi
also
import
role
field
context
posttransl
modif
ptm
protein
signific
impact
potenti
modif
known
includ
phosphoryl
glycosyl
acetyl
myristoyl
palmitoyl
methyl
sulfat
prenyl
ubiquityl
http
wwwabrforgindexcfm
dmhome
past
two
decad
sensit
ms
method
refin
determin
type
site
protein
modif
seldom
predict
genom
sequenc
protein
modif
regulatori
revers
notabl
phosphoryl
control
protein
function
local
complex
format
stabil
activ
differ
mechan
result
extens
research
know
human
protein
modifi
phosphoryl
phosphoryl
residu
tyrosin
protein
phosphoryl
one
hallmark
proteinprotein
interact
ppi
underli
signal
network
mani
case
aberr
protein
kinas
activ
drive
diseaseassoci
derang
signal
pathway
aim
would
design
drug
effect
disrupt
aberr
proteinphosphorylationbas
enzymat
activ
epigenet
phenomena
pharmacoproteom
tailor
therapi
base
proteom
knowledg
expect
take
central
role
process
recent
studi
describ
cellbas
drug
discoveri
platform
base
phosphospecif
flow
cytometri
phosphoflow
research
abl
screen
inhibitor
multipl
endogen
kinas
signal
pathway
heterogen
primari
cell
popul
singlecel
level
protein
microarray
examin
proteinprotein
recognit
event
ie
phosphoryl
global
highthroughput
manner
use
profil
cellular
signal
pathway
way
possibl
gene
array
activ
level
protein
particular
pathway
therebi
assess
real
time
tailor
treatment
patient
cellular
circuitri
advantag
protein
microarray
lie
abil
provid
map
known
cellular
signal
protein
gener
reflect
state
inform
flow
protein
network
individu
specimen
identif
crucial
node
interact
within
network
see
later
potenti
start
point
drug
develop
design
individu
therapeut
regimen
accur
annot
peptid
modif
unrestrict
databas
search
reveal
posttransl
modif
well
sequenc
polymorph
monitor
differ
phosphoprotein
level
also
help
identifi
treatmentacquir
resist
chemotherapi
effect
imatinib
tyrosin
phosphoproteom
bcrabl
posit
leukemia
cell
line
examin
proteom
approach
investig
reveal
site
tyrosin
phosphoryl
correspond
differ
protein
affin
column
chromatographi
use
immobil
pyrido
pyrimidin
deriv
success
use
select
protein
kinas
bound
matrix
identifi
use
ms
demonstr
fact
pyrido
pyrimidin
kinas
inhibitor
low
specif
similar
methodolog
approach
appli
studi
kinas
inhibitor
demonstr
cyclin
gassoci
kinas
gak
almost
potent
inhibit
protein
express
subsequ
treatment
hdaci
trichostatina
studi
human
pancrea
ductal
carcinoma
cell
line
use
malditof
ms
trichostatina
appear
upregul
protein
promot
cell
death
downregul
protein
favor
cell
growth
similarli
modul
protein
involv
prolifer
cell
cycl
regul
apoptosi
gene
express
colon
carcinoma
cell
pharmacoproteom
approach
found
particularli
use
identif
molecular
alter
implic
type
diabet
character
exist
new
drug
research
shown
sever
physiolog
factor
lead
chang
plasma
proteom
peptidom
includ
stress
sleep
sport
train
eat
meal
pregnanc
exposur
toxic
agent
includ
drug
also
detect
use
proteom
lead
distinct
field
studi
known
toxicoproteom
recent
protein
plasma
worker
expos
benzen
analyz
two
drug
discoveri
today
volum
number
decemb
human
erythrocyt
proteinprotein
interact
network
interactom
node
network
known
rbc
protein
link
connect
node
correspond
known
interact
significantli
upregul
protein
profil
found
worker
expos
toxic
chemic
cell
receptor
b
chain
matrix
thu
plasmat
cell
receptor
b
chain
may
use
indic
earli
detect
exposur
benzen
compar
proteom
analysi
human
plasma
allow
qian
et
al
identifi
protein
significantli
increas
lipopolysaccharid
administr
studi
plasma
worker
occup
expos
polycycl
hydrocarbon
reveal
sever
protein
marker
exposur
use
techniqu
truncat
form
discov
serum
sampl
patient
present
sever
acut
respiratori
syndrom
anoth
studi
involv
patient
syndrom
sampl
reveal
total
differenti
spot
correspond
acut
phase
protein
author
also
identifi
protein
peroxiredoxin
ii
previous
detect
plasma
investig
plasma
protein
interact
metal
remain
rel
new
challeng
arena
toxicoproteom
current
studi
includ
identif
protein
carrier
determin
toxic
metal
concentr
requir
sensit
analyt
techniqu
power
equip
thank
search
suitabl
quantit
techniqu
field
drug
design
proteom
may
almost
develop
induct
coupl
plasma
ms
icpm
anoth
relev
field
pharmacoproteom
applic
elucid
biolog
mechan
drug
resist
drugresist
cell
altern
protein
form
appear
prevent
drug
bind
activ
site
andor
execut
signal
effect
independ
regul
nativ
protein
form
methodolog
proteom
seem
highli
applic
search
drugresist
protein
form
drugresist
proteom
context
plasma
proteom
aspirin
acetylsalicyl
acid
asa
sensit
asaresist
coronari
ischem
patient
analyz
express
one
isotyp
fibrinogen
g
chain
three
isotyp
haptoglobin
increas
asaresist
patient
well
three
vitamin
bind
protein
dbp
isotyp
suggest
dbp
regul
inhibitori
effect
asa
platelet
reduc
inhibitori
effect
asa
thromboxan
product
field
oncolog
proteom
becom
wide
use
identif
tumorspecif
protein
marker
pharmacoproteom
found
place
evalu
chemotherapi
particularli
character
drugresist
mechan
identifi
import
interact
blood
protein
emerg
anoth
focu
bloodbas
proteom
research
mani
protein
circul
blood
singl
entiti
multicompon
complex
compris
blood
interactom
proteinprotein
interact
ppi
inform
extract
current
avail
databas
interact
silico
approach
littl
current
known
interact
given
protein
blood
whether
interact
biolog
relev
examin
protein
complex
howev
often
yield
inform
protein
function
identif
interact
may
bring
light
import
inform
design
new
small
molecul
therapeut
conceptu
framework
contrast
singl
protein
singl
pathway
approach
previous
domin
biolog
combin
proteom
silico
approach
allow
one
identifi
diseas
andor
drugrel
chang
proteom
also
predict
chang
protein
interactom
network
associ
diseaserel
chang
function
also
predict
modif
associ
ptm
chang
occur
result
specif
diseas
stage
diseas
well
drug
gene
therapi
treatment
link
approach
repres
futur
clinic
identif
specif
diseas
current
stage
sever
effect
side
effect
variou
treatment
clearli
interactom
plasma
protein
far
realiti
present
complex
simplic
human
erythrocyt
cell
structur
instead
made
optim
cell
proteom
studi
fact
nucleat
cell
contain
protein
red
blood
cell
rbc
lack
nuclei
organel
contain
far
fewer
comprehens
list
rbc
protein
known
date
contain
entri
obtain
use
proteom
technolog
result
ppi
network
depict
fig
network
present
deriv
protein
interact
data
obtain
unifi
human
interactom
unihi
correl
report
unihi
deriv
gene
express
experi
repres
measur
confid
interact
knowledg
ppi
continu
increas
owe
advanc
proteom
research
expect
addit
deeper
understand
erythrocyt
protein
complement
relat
function
also
possibl
understand
chang
rbc
proteom
interactom
affect
develop
erythrocyt
disord
promis
proteomicbas
profil
oppos
gene
transcript
profil
alon
result
prognost
signatur
deriv
drug
target
protein
gene
pathway
analysi
provid
direct
therapeut
mitig
dark
cloud
horizon
may
extend
use
pharmacoproteom
beyond
molecular
network
analysi
patienttailor
therapi
includ
risk
stratif
predispost
test
like
rais
larger
societ
issu
particularli
climat
cost
contain
power
combin
pharmacoproteom
interactom
may
win
despit
cost
furnish
new
target
therapi
diseas
prevent
well
posttherapi
monitor
short
techniqu
provid
window
presenc
sever
specif
diseas
drug
gene
therapi
treatment
also
use
identifi
diseaseand
drugrel
chang
proteom
also
predict
chang
protein
interactom
network
associ
diseaserel
chang
function
without
doubt
link
approach
repres
futur
cost
effect
noninvas
identif
specif
clinic
diseas
prognosi
effect
treatment
